Login Register Cart 0
Systematic Review Article

检测循环游离DNA诊断中国人群肝细胞癌:系统回顾和荟萃分析

卷 31, 期 22, 2024

发表于: 12 September, 2023

页: [3345 - 3359] 页: 15

弟呕挨: 10.2174/0929867330666230622114235

价格: $65

摘要

背景：人们已经知道无细胞循环DNA很多年了，但这一知识并没有对诊断有益。在本荟萃分析中，我们研究了循环无细胞DNA在HCC患者中的诊断作用，以寻找HCC早期检测的可靠生物标志物。 材料与方法：我们使用Science Direct、Web of Science、PubMed/Medline、Scopus、Google Scholar和Embase进行了系统的文献检索，检索时间截止到2022年4月1日。Meta-Disc V.1.4和Comprehensive Meta-Analysis V.3.3软件计算了cfDNA作为HCC患者生物标志物的合并特异性、敏感性、曲线下面积(AUC)、诊断优势比(DOR)、阳性似然比(PLR)、阴性似然比(NLR) Q*指数和总受者操作特征(SROC)。此外，根据样品类型(血清/血浆)和检测方法(MS-PCR/甲基化)进行了亚组分析。 结果：共有7篇文章(9项研究)纳入697名受试者(485例和212例对照)。总体合并敏感性、特异性、阳性似然比(PLR)、阴性似然比(NLR)、诊断优势比(DOR)和曲线下面积(AUC)分别为0.706 (95% CI: 0.671 ~ 0.739)、0.905 (95% CI: 0.865 ~ 0.937)、6.66 (95% CI: 4.36 ~ 10.18)、0.287 (95% CI: 0.185 ~ 0.445)、28.40 (95% CI: 13.01 ~ 62.0)和0.93。我们对诊断价值进行了亚组分析，结果显示血浆样本比血清具有更好的诊断价值。 结论：该荟萃分析表明，cfDNA可以作为诊断HCC患者的一种公平的生物标志物。

关键词: 循环游离DNA，肝细胞癌，生物标志物，液体活检，分子诊断，cfDNA。

« Previous Next »
[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
McGlynn, K.A.; Petrick, J.L.; El-Serag, H.B. Epidemiology of hepatocellular carcinoma. Hepatology, 2021, 73(S1)(Suppl. 1), 4-13.
[http://dx.doi.org/10.1002/hep.31288] [PMID: 32319693]
[3]
Petrick, J.L.; Florio, A.A.; Znaor, A.; Ruggieri, D.; Laversanne, M.; Alvarez, C.S.; Ferlay, J.; Valery, P.C.; Bray, F.; McGlynn, K.A. International trends in hepatocellular carcinoma incidence, 1978–2012. Int. J. Cancer, 2020, 147(2), 317-330.
[http://dx.doi.org/10.1002/ijc.32723] [PMID: 31597196]
[4]
Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2021, 7(1), 6.
[http://dx.doi.org/10.1038/s41572-020-00240-3] [PMID: 33479224]
[5]
Mirzaei H.; Sahebkar A.; Jaafari M.R.; Goodarzi M.; Mirzaei H.R. Diagnostic and therapeutic potential of exosomes in cancer: The beginning of a new tale? J. Cell. Physiol.2017, 232(12), 3251-3260.
[http://dx.doi.org/10.1002/jcp.25739]
[6]
Sahebkar, A.; Aalami, A.H.; Aalami, F. Gastric cancer and circulating microRNAs: An updated systematic review and diagnostic meta-analysis. Curr. Med. Chem., 2023, 30(33), 3798-3814.
[http://dx.doi.org/10.2174/0929867330666221121155905] [PMID: 36411580]
[7]
Aalami, A.H.; Hoseinzadeh, M.; Hosseini Manesh, P.; Jiryai Sharahi, A.; Kargar Aliabadi, E. Carcinogenic effects of heavy metals by inducing dysregulation of microRNAs: A review. Mol. Biol. Rep., 2022, 49(12), 12227-12238.
[http://dx.doi.org/10.1007/s11033-022-07897-x] [PMID: 36269534]
[8]
Aalami, A.H.; Abdeahad, H.; Shoghi, A.; Mesgari, M.; Amirabadi, A.; Sahebkar, A. Brain tumors and circulating micrornas: A systematic review and diagnostic meta-analysis. Expert Rev. Mol. Diagn., 2022, 22(2), 201-211.
[http://dx.doi.org/10.1080/14737159.2022.2019016] [PMID: 34906021]
[9]
Aalami, A.H.; Abdeahad, H.; Aalami, F.; Amirabadi, A. Can microRNAs be utilized as tumor markers for recurrence following nephrectomy in renal cell carcinoma patients? A meta-analysis provides the answer. Urol. Oncol., 2023, 41(1), 52.e1-52.e10.
[10]
Qasemi Rad, M.; Pouresmaeil, V.; Hosseini Mojahed, F.; Amirabadi, A.; Aalami, A.H. Clinicopathological utility of miR-203a-3p in diagnosing colorectal cancer. Mol. Biol. Rep., 2022, 49(7), 6975-6985.
[http://dx.doi.org/10.1007/s11033-022-07465-3] [PMID: 35511316]
[11]
Han, D.S.C.; Lo, Y.M.D. The nexus of cfDNA and nuclease biology. Trends Genet., 2021, 37(8), 758-770.
[http://dx.doi.org/10.1016/j.tig.2021.04.005] [PMID: 34006390]
[12]
Moss, J.; Magenheim, J.; Neiman, D.; Zemmour, H.; Loyfer, N.; Korach, A.; Samet, Y.; Maoz, M.; Druid, H.; Arner, P.; Fu, K.Y.; Kiss, E.; Spalding, K.L.; Landesberg, G.; Zick, A.; Grinshpun, A.; Shapiro, A.M.J.; Grompe, M.; Wittenberg, A.D.; Glaser, B.; Shemer, R.; Kaplan, T.; Dor, Y. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun., 2018, 9(1), 5068.
[http://dx.doi.org/10.1038/s41467-018-07466-6] [PMID: 30498206]
[13]
Daraghmeh, D.N.; King, C.; Wiese, M.D. A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. Pharmacol. Res., 2021, 173, 105887.
[http://dx.doi.org/10.1016/j.phrs.2021.105887] [PMID: 34536550]
[14]
Meddeb, R.; Dache, Z.A.A.; Thezenas, S.; Otandault, A.; Tanos, R.; Pastor, B.; Sanchez, C.; Azzi, J.; Tousch, G.; Azan, S.; Mollevi, C.; Adenis, A.; El Messaoudi, S.; Blache, P.; Thierry, A.R. Quantifying circulating cell-free DNA in humans. Sci. Rep., 2019, 9(1), 5220.
[http://dx.doi.org/10.1038/s41598-019-41593-4] [PMID: 30914716]
[15]
Alborelli, I.; Generali, D.; Jermann, P.; Cappelletti, M.R.; Ferrero, G.; Scaggiante, B.; Bortul, M.; Zanconati, F.; Nicolet, S.; Haegele, J.; Bubendorf, L.; Aceto, N.; Scaltriti, M.; Mucci, G.; Quagliata, L.; Novelli, G. Cell-free DNA analysis in healthy individuals by next-generation sequencing: A proof of concept and technical validation study. Cell Death Dis., 2019, 10(7), 534.
[http://dx.doi.org/10.1038/s41419-019-1770-3] [PMID: 31296838]
[16]
Heitzer, E.; Haque, I.S.; Roberts, C.E.S.; Speicher, M.R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet., 2019, 20(2), 71-88.
[http://dx.doi.org/10.1038/s41576-018-0071-5] [PMID: 30410101]
[17]
Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Swanton, C.; Seiden, M.V.; Liu, M.C.; Oxnard, G.R.; Klein, E.A.; Smith, D.; Richards, D.; Yeatman, T.J.; Cohn, A.L.; Lapham, R.; Clement, J.; Parker, A.S.; Tummala, M.K.; McIntyre, K.; Sekeres, M.A.; Bryce, A.H.; Siegel, R.; Wang, X.; Cosgrove, D.P.; Abu-Rustum, N.R.; Trent, J.; Thiel, D.D.; Becerra, C.; Agrawal, M.; Garbo, L.E.; Giguere, J.K.; Michels, R.M.; Harris, R.P.; Richey, S.L.; McCarthy, T.A.; Waterhouse, D.M.; Couch, F.J.; Wilks, S.T.; Krie, A.K.; Balaraman, R.; Restrepo, A.; Meshad, M.W.; Rieger-Christ, K.; Sullivan, T.; Lee, C.M.; Greenwald, D.R.; Oh, W.; Tsao, C-K.; Fleshner, N.; Kennecke, H.F.; Khalil, M.F.; Spigel, D.R.; Manhas, A.P.; Ulrich, B.K.; Kovoor, P.A.; Stokoe, C.; Courtright, J.G.; Yimer, H.A.; Larson, T.G.; Swanton, C.; Seiden, M.V.; Cummings, S.R.; Absalan, F.; Alexander, G.; Allen, B.; Amini, H.; Aravanis, A.M.; Bagaria, S.; Bazargan, L.; Beausang, J.F.; Berman, J.; Betts, C.; Blocker, A.; Bredno, J.; Calef, R.; Cann, G.; Carter, J.; Chang, C.; Chawla, H.; Chen, X.; Chien, T.C.; Civello, D.; Davydov, K.; Demas, V.; Desai, M.; Dong, Z.; Fayzullina, S.; Fields, A.P.; Filippova, D.; Freese, P.; Fung, E.T.; Gnerre, S.; Gross, S.; Halks-Miller, M.; Hall, M.P.; Hartman, A-R.; Hou, C.; Hubbell, E.; Hunkapiller, N.; Jagadeesh, K.; Jamshidi, A.; Jiang, R.; Jung, B.; Kim, T.H.; Klausner, R.D.; Kurtzman, K.N.; Lee, M.; Lin, W.; Lipson, J.; Liu, H.; Liu, Q.; Lopatin, M.; Maddala, T.; Maher, M.C.; Melton, C.; Mich, A.; Nautiyal, S.; Newman, J.; Newman, J.; Nicula, V.; Nicolaou, C.; Nikolic, O.; Pan, W.; Patel, S.; Prins, S.A.; Rava, R.; Ronaghi, N.; Sakarya, O.; Satya, R.V.; Schellenberger, J.; Scott, E.; Sehnert, A.J.; Shaknovich, R.; Shanmugam, A.; Shashidhar, K.C.; Shen, L.; Shenoy, A.; Shojaee, S.; Singh, P.; Steffen, K.K.; Tang, S.; Toung, J.M.; Valouev, A.; Venn, O.; Williams, R.T.; Wu, T.; Xu, H.H.; Yakym, C.; Yang, X.; Yecies, J.; Yip, A.S.; Youngren, J.; Yue, J.; Zhang, J.; Zhang, L.; Zhang, L.Q.; Zhang, N.; Curtis, C.; Berry, D.A. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann. Oncol., 2020, 31(6), 745-759.
[http://dx.doi.org/10.1016/j.annonc.2020.02.011] [PMID: 33506766]
[18]
Fang, Y.S.; Wu, Q.; Zhao, H.C.; Zhou, Y.; Ye, L.; Liu, S.S.; Li, X.X.; Du, W.D. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. Expert Rev. Gastroenterol. Hepatol., 2021, 15(9), 1065-1076.
[http://dx.doi.org/10.1080/17474124.2021.1900731] [PMID: 33691550]
[19]
Qi, F.; Zhou, A.; Yan, L.; Yuan, X.; Wang, D.; Chang, R.; Zhang, Y.; Shi, F.; Han, X.; Hou, J.; Wei, L.; Zhang, X. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. J. Clin. Lab. Anal., 2020, 34(5), e23158.
[http://dx.doi.org/10.1002/jcla.23158] [PMID: 31821607]
[20]
Piñero, F.; Dirchwolf, M.; Pessôa, M.G. Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells, 2020, 9(6), 1370.
[http://dx.doi.org/10.3390/cells9061370] [PMID: 32492896]
[21]
de Lima, L.T.F.; Broszczak, D.; Zhang, X.; Bridle, K.; Crawford, D.; Punyadeera, C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer, 2020, 1874(2), 188451.
[http://dx.doi.org/10.1016/j.bbcan.2020.188451] [PMID: 33065194]
[22]
Wang, Y.; Wang, Y.; Huang, A.; Jiang, R.; Zheng, J.; Li, Z. The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers to diagnose hepatocellular carcinoma; AACR, 2020.
[http://dx.doi.org/10.1158/1538-7445.AM2020-782]
[23]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Moher, D. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J. Clin. Epidemiol., 2021, 134, 103-112.
[http://dx.doi.org/10.1016/j.jclinepi.2021.02.003] [PMID: 33577987]
[24]
Moses, L.E.; Shapiro, D.; Littenberg, B. Combining independent studies of a diagnostic test into a summary roc curve: Data-analytic approaches and some additional considerations. Stat. Med., 1993, 12(14), 1293-1316.
[http://dx.doi.org/10.1002/sim.4780121403] [PMID: 8210827]
[25]
Furuya-Kanamori, L.; Kostoulas, P.; Doi, S.A.R. A new method for synthesizing test accuracy data outperformed the bivariate method. J. Clin. Epidemiol., 2021, 132, 51-58.
[http://dx.doi.org/10.1016/j.jclinepi.2020.12.015] [PMID: 33333166]
[26]
Sha, Y.S.; Chen, J.F. MRI-based radiomics for the diagnosis of triple-negative breast cancer: A meta-analysis. Clin. Radiol., 2022, 77(9), 655-663.
[http://dx.doi.org/10.1016/j.crad.2022.04.015] [PMID: 35641339]
[27]
Zeng, Q-S; Zhao, Z-J; Nie, J; Zou, M; Yang, J-H; Zhang, J-Z Efficacy and safety of endoscopic submucosal dissection for dysplasia in ulcerative colitis patients: A systematic review and meta-analysis. Gastroenterol Res Pract, 2022, 2022, 9556161.
[http://dx.doi.org/10.1155/2022/9556161] [PMID: 35126511]
[28]
Sedgwick, P. Spearman's rank correlation coefficient. BMJ, 2014, 349, g7327.
[http://dx.doi.org/10.1136/bmj.g7327]
[29]
Akoglu, H. User’s guide to correlation coefficients. Turk. J. Emerg. Med., 2018, 18(3), 91-93.
[http://dx.doi.org/10.1016/j.tjem.2018.08.001] [PMID: 30191186]
[30]
Huang, Z.; Hua, D.; Hu, Y.; Cheng, Z.; Zhou, X.; Xie, Q.; Wang, Q.; Wang, F.; Du, X.; Zeng, Y. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol. Oncol. Res., 2012, 18(2), 271-276.
[http://dx.doi.org/10.1007/s12253-011-9438-z] [PMID: 21779787]
[31]
Huang, A.; Zhang, X.; Zhou, S.L.; Cao, Y.; Huang, X.W.; Fan, J.; Yang, X.R.; Zhou, J. Plasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinoma. J. Cancer, 2016, 7(13), 1798-1803.
[http://dx.doi.org/10.7150/jca.15618] [PMID: 27698918]
[32]
Sun, F.K.; Fan, Y.C.; Zhao, J.; Zhang, F.; Gao, S.; Zhao, Z.H.; Sun, Q.; Wang, K. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig. Dis. Sci., 2013, 58(4), 1010-1015.
[http://dx.doi.org/10.1007/s10620-012-2462-3] [PMID: 23108564]
[33]
Chan, K.C.A.; Lai, P.B.S.; Mok, T.S.K.; Chan, H.L.Y.; Ding, C.; Yeung, S.W.; Lo, Y.M.D. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin. Chem., 2008, 54(9), 1528-1536.
[http://dx.doi.org/10.1373/clinchem.2008.104653] [PMID: 18653827]
[34]
Ji, X.F.; Fan, Y-C.; Gao, S.; Yang, Y.; Zhang, J-J.; Wang, K. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J. Gastroenterol., 2014, 20(16), 4723-4729.
[http://dx.doi.org/10.3748/wjg.v20.i16.4723] [PMID: 24782625]
[35]
Zhang, Y.J.; Wu, H.C.; Shen, J.; Ahsan, H.; Tsai, W.Y.; Yang, H.I.; Wang, L.Y.; Chen, S.Y.; Chen, C.J.; Santella, R.M. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res., 2007, 13(8), 2378-2384.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-1900] [PMID: 17438096]
[36]
Jiang, P.; Chan, C.W.M.; Chan, K.C.A.; Cheng, S.H.; Wong, J.; Wong, V.W.S.; Wong, G.L.H.; Chan, S.L.; Mok, T.S.K.; Chan, H.L.Y.; Lai, P.B.S.; Chiu, R.W.K.; Lo, Y.M.D. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. USA, 2015, 112(11), E1317-E1325.
[http://dx.doi.org/10.1073/pnas.1500076112] [PMID: 25646427]
[37]
Ranganathan, P.; Aggarwal, R. Understanding the properties of diagnostic tests-Part 2: Likelihood ratios. Perspect. Clin. Res., 2018, 9(2), 99-102.
[http://dx.doi.org/10.4103/picr.PICR_41_18] [PMID: 29862204]
[38]
Jones, C.M.; Athanasiou, T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann. Thorac. Surg., 2005, 79(1), 16-20.
[http://dx.doi.org/10.1016/j.athoracsur.2004.09.040] [PMID: 15620907]
[39]
Park, H.J.; Jang, H.Y.; Kim, S.Y.; Lee, S.J.; Won, H.J.; Byun, J.H.; Choi, S.H.; Lee, S.S.; An, J.; Lim, Y.S. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J. Hepatol., 2020, 72(4), 718-724.
[http://dx.doi.org/10.1016/j.jhep.2019.12.001] [PMID: 31836549]
[40]
Li, B; Huang, H; Huang, R SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma. Dis Markers, 2020, 2020, 6289063.
[http://dx.doi.org/10.1155/2020/6289063] [PMID: 33178361]
[41]
Yan, L.; Chen, Y.; Zhou, J.; Zhao, H.; Zhang, H.; Wang, G. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int. J. Infect. Dis., 2018, 67, 92-97.
[http://dx.doi.org/10.1016/j.ijid.2017.12.002] [PMID: 29229500]
[42]
Howell, J.; Atkinson, S.R.; Pinato, D.J.; Knapp, S.; Ward, C.; Minisini, R.; Burlone, M.E.; Leutner, M.; Pirisi, M.; Büttner, R.; Khan, S.A.; Thursz, M.; Odenthal, M.; Sharma, R. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur. J. Cancer, 2019, 116, 56-66.
[http://dx.doi.org/10.1016/j.ejca.2019.04.014] [PMID: 31173963]
[43]
Pezzuto, F.; Buonaguro, L.; Buonaguro, F.; Tornesello, M. The role of circulating free DNA and microRNA in non-invasive diagnosis of HBV-and HCV-related hepatocellular carcinoma. Int. J. Mol. Sci., 2018, 19(4), 1007.
[http://dx.doi.org/10.3390/ijms19041007] [PMID: 29597259]
[44]
Ma, K.; Liu, J.; Wang, Y.; Zhong, Y.; Wu, Z.; Fan, R.; Guo, S. Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma. J. Gastrointest. Oncol., 2020, 11(6), 1350-1363.
[http://dx.doi.org/10.21037/jgo-20-509] [PMID: 33457006]
[45]
Ren, N.; Ye, Q-H.; Qin, L-X.; Zhang, B-H.; Liu, Y-K.; Tang, Z-Y. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J. Gastroenterol., 2006, 12(24), 3911-3914.
[http://dx.doi.org/10.3748/wjg.v12.i24.3911] [PMID: 16804981]
[46]
Nakatsuka, T.; Nakagawa, H.; Hayata, Y.; Wake, T.; Yamada, T.; Nishibatake Kinoshita, M.; Nakagomi, R.; Sato, M.; Minami, T.; Uchino, K.; Enooku, K.; Kudo, Y.; Tanaka, Y.; Kishikawa, T.; Otsuka, M.; Tateishi, R.; Koike, K. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. J. Gastroenterol., 2021, 56(5), 456-469.
[http://dx.doi.org/10.1007/s00535-021-01773-4] [PMID: 33712873]
[47]
Coto-Llerena, M.; Terracciano, L.M.; von Flüe, M.; Ng, C.K.; Piscuoglio, S. Cell-free DNA in hepatocellular carcinoma. Precision medicine for investigators, practitioners and providers; Elsevier, 2020, pp. 199-209.
[http://dx.doi.org/10.1016/B978-0-12-819178-1.00019-8]
[48]
Chen, W.; Tang, D.; Tang, D.; Dai, Y. Epigenetic silencing of ZIC4 contributes to cancer progression in hepatocellular carcinoma. Cell Death Dis., 2020, 11(10), 906.
[http://dx.doi.org/10.1038/s41419-020-03109-1] [PMID: 33097694]
[49]
Xu, G.; Zhou, X.; Xing, J.; Xiao, Y.; Jin, B.; Sun, L.; Yang, H.; Du, S.; Xu, H.; Mao, Y. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell Int., 2020, 20(1), 547.
[http://dx.doi.org/10.1186/s12935-020-01638-5] [PMID: 33292241]
[50]
Cozma, A.; Fodor, A.; Vulturar, R.; Sitar-Tăut, A.V.; Orăşan, O.H.; Mureşan, F.; Login, C.; Suharoschi, R. DNA methylation and micro-RNAs: the most recent and relevant biomarkers in the early diagnosis of hepatocellular carcinoma. Medicina (Kaunas), 2019, 55(9), 607.
[http://dx.doi.org/10.3390/medicina55090607] [PMID: 31546948]
[51]
Mohamed, N.A.; Swify, E.M.; Amin, N.F.; Soliman, M.M.; Tag-Eldin, L.M.; Elsherbiny, N.M. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? Arab J. Gastroenterol., 2012, 13(3), 111-115.
[http://dx.doi.org/10.1016/j.ajg.2012.06.009] [PMID: 23122451]
[52]
Zhang, J.; Yuan, Y.; Gao, S.; Zhao, X.; Li, H. Diagnostic performance of circulating cell-free DNA for hepatocellular carcinoma: a systematic review and meta-analysis. Biomarkers Med., 2021, 15(3), 219-239.
[http://dx.doi.org/10.2217/bmm-2020-0334] [PMID: 33470842]

Rights & Permissions Print Cite
Article Metrics
20
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy